SEEDNCT05786443
Safety and Efficacy of Empagliflozin in Hemodialysis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Site details revised at 2 of 2 sites
- Notable Eligibility criteria expanded, about 9 words
- Secondary endpoints: details revised at 3 of 11 entries
- Site details revised at 1 of 2 sites
- Notable Primary and study completion dates: Dec 30, 2025 to Dec 30, 2026v6
- Notable Eligibility criteria shortened, about 2 wordsv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 8, 2023 to Jan 31, 2024
- Site details revised at 2 of 2 sites
Show 2 earlier versionsHide 2 earlier versions
- Notable Start date: Aug 15, 2023 to Dec 8, 2023v3
- Notable Start date: Jun 1, 2023 to Aug 15, 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in Extracellular Volume from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Change in Intracellular Volume from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Change in Total Body Water from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Change in 24-Hour Urine Volume from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Secondary (11)
Change in 24-Hour Urine Albumin Excretion from Baseline to 12 Weeks
Change in 24-Hour Ambulatory Blood Pressure from Baseline to 12 Weeks
Change in Heart Rate Variability from Baseline to 12 Weeks
Incidence of Intra-Dialytic Hypotension
Incidence of Inter-Dialytic Hypotension
Show 6 moreShow less
Incidence of Serious Hypotension
Incidence of Non-Serious Hypoglycemia
Incidence of Serious Hypoglycemia
Incidence of Ketoacidosis
Number of Adverse Events
Number of Serious Adverse Events
Arms and interventions
EmpagliflozinExperimental
Participants with end-stage kidney disease (ESRD) initiating hemodialysis will receive Empagliflozin 10 mg daily for 12 weeks.
PlaceboPlacebo comparator
Participants with ESRD initiating hemodialysis will receive Empagliflozin-matching placebo daily for 12 weeks.
Drugs: Empagliflozin 10 MG, Placebo
Sites
2 sites in 1 country